免疫介导炎症性疾病中的免疫耐受生物标志物:临床管理新纪元?
本文综述了免疫介导炎症性疾病中免疫稳态生物标志物的现有知识及其在预测和实现持续无药缓解中的应用。文章汇总了类风湿关节炎、幼年特发性关节炎和炎症性肠病等疾病中前瞻性停药研究的证据,并探讨了临床、血清学、蛋白质组学、代谢组学、细胞和微生物组生物标志物,最后讨论了临床转化所需步骤及潜在变革性影响。
要点
- 持续缓解已成为许多免疫介导炎症性疾病患者的可及目标,但停药决策缺乏可靠依据。
- 现有证据来自类风湿关节炎、幼年特发性关节炎和炎症性肠病等的前瞻性停药研究。
- 多种类型生物标志物有望预测无药缓解,但临床转化仍需进一步研究。
核心结论
- 免疫稳态生物标志物有望指导免疫介导炎症性疾病患者停药决策并预测持续无药缓解。
研究设计与样本
- 综述汇总了类风湿关节炎、幼年特发性关节炎和炎症性肠病等疾病中免疫调节药物停药的前瞻性研究证据。
主要发现
- 综述涵盖了临床、血清学、蛋白质组学、代谢组学、细胞和微生物组生物标志物与免疫稳态的现有证据。
临床怎么用
- 生物标志物若成功临床转化,可能变革免疫介导炎症性疾病患者的管理方式。
局限性
- 生物标志物的临床转化仍需完成必要步骤,目前尚未实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Modern therapeutic agents and treatment regimens have made sustained remission an attainable target for many patients across a spectrum of immune-mediated inflammatory diseases, albeit at the risk of adverse events and the expense of drug prescription and safety monitoring. Clinicians and patients are thus increasingly faced with a novel treatment dilemma: whether and how best to stop immunomodulatory treatment in patients who achieve remission. In this final paper in a Series on therapeutic tolerance induction, we summarise our current knowledge of biomarkers of immune homeostasis in immune-mediated inflammatory diseases and their application to the prediction and attainment of sustained drug-free remission. We summarise evidence from prospective studies of immunomodulatory drug cessation across a range of immune-mediated inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, and inflammatory bowel disease. We also consider current evidence for clinical, serological, proteomic, metabolomic, cellular, and microbiomic biomarkers of immune homeostasis. Finally, we discuss the steps necessary for clinical translation of these biomarkers, as well as the potential transformative effect of these biomarkers on management of patients with immune-mediated inflammatory diseases if clinical translation is successfully achieved.
引用
- Baker KF, Sim JPX, Isaacs JD, et al. Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management? Lancet Rheumatol. 2021. PMID: 38279392. doi:10.1016/S2665-9913(21)00069-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。